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Background: To perform a meta-analysis evaluating the diagnostic ability of fecal lactoferrin (FL) to distinguish
inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS).
Methods: The Medline, EMBASE, Web of Science, Cochrane library and CNKI databases were systematically
searched for studies that used FL concentrations to distinguish between IBD and IBS. The sensitivity, specificity, and
other diagnostic indexes of FL were pooled using a random-effects model.
Results: Seven studies, involving 1012 patients, were eligible for inclusion. In distinguishing IBD from IBS, FL had a
pooled sensitivity of 0.78 (95% confidence interval [CI]: 0.75, 0.82), a specificity of 0.94 (95% CI: 0.91, 0.96), a positive
likelihood ratio of 12.31 (95% CI: 5.93, 29.15), and a negative likelihood ratio of 0.23 (95% CI: 0.18, 0.29). The area
under the summary receiver-operating characteristic curve was 0.94 (95% CI: 0.90, 0.98) and the diagnostic odds
ratio was 52.65 (95% CI: 25.69, 107.91).
Conclusions: FL, as a noninvasive and simple marker, is useful in differentiating between IBD and IBS.
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Inflammatory bowel disease (IBD) and irritable bowel syn-
drome (IBS) are common conditions that may present
with a similar symptom complex of abdominal pain and
altered bowel habits. However, the two conditions differ
markedly in their pathophysiology, prognosis and thera-
peutic approaches. IBD represents a group of idiopathic,
chronic, inflammatory intestinal conditions [1], commonly
requires a lifetime of medical care, and can even cause sig-
nificant morbidity. In contrast, IBS is a chronic, functional
gastrointestinal disorder without inflammation [2], with
most IBS patients having a favorable prognosis. Despite
existing diagnostic criteria, such as the Rome criteria, it
remains difficult to distinguish IBD from IBS using symp-
toms and signs only, especially in the absence of rectal
bleeding and systemic illness. As clinical differentiation* Correspondence: wspan223@163.com
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unless otherwise stated.remains challenging and may delay effective treatment,
most patients with IBS are evaluated by endoscopy and
radiographic imaging to exclude a diagnosis of IBD. This
not only exposes patients to the inherent risks associated
with these procedures, but increases their economic bur-
den [3]. Less invasive and less expensive diagnostic
methods are needed to more effectively rule out IBD in
primary care patients with chronic abdominal complaints.
Fecal measurements of potential biomarkers are nonin-
vasive diagnostic tests for intestinal mucosal inflammation
and may correlate well with disease activity. Several
neutrophil-granular proteins released by activated neu-
trophils may constitute fecal markers of intestinal inflam-
mation, including lactoferrin (LF), calprotectin (Cal),
polymorphonuclear neutrophil-elastase (PMN-e), and lyso-
zyme (Lys) [4], with Cal and LF appearing to be the most
promising surrogate biomarkers. Cal is a calcium- and
zinc-binding protein that constitutes up to 60% of the total
cytosolic protein content of neutrophils [5]. Cal has been
shown to reflect neutrophil migration in the intestines oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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alternative to 111indium labeled radioactive techniques [6].
LF is an iron binding glycoprotein with a molecular mass
of about 80 kDa that is present in various secretory fluids,
such as milk, saliva, tears, and nasal secretions [7]. LF is a
component of the innate immune system, with antimicro-
bial activity as a bactericide and fungicide, as well as being
a major constituent of neutrophil granules that is released
during apoptosis [8]. During intestinal inflammation poly-
morphonuclear neutrophils infiltrate the mucosa, increas-
ing LF concentration in feces proportional to neutrophil
translocation to the GI tract [9]. Studies investigating
whether FL can be used as a noninvasive marker to distin-
guish IBD from non inflammatory conditions, especially
IBS, have yielded variable results [3,10-18]. We therefore
designed a meta-analysis to assess the overall diagnostic
capacity of FL in discriminating IBD from IBS.
Methods
Literature search
Medline (using PubMed as the search engine), EMBASE,
Web of science, Cochrane library and China National
Knowledge Infrastructure (CNKI) databases were searched
by two reviewers (XZ and WX) independently for relevant
articles published in English and Chinese up to November
2013. The MeSH headings and key words used were
“fecal lactoferrin”, “lactoferrin and inflammatory bowel
disease”, “lactoferrin and irritable bowel syndrome”,
“IBD and IBS”, and “lactoferrin and intestinal inflamma-
tion”. Further searches included combinations of “lactofer-
rin” with “enteritis”, “ileitis”, “enteritidis”, and “esoenteritis”.
We also screened the reference lists of included studies
and review articles. The results were then hand searched
for eligible studies.
Study eligibility
Studies were included if they met the following criteria:
1) assessed the diagnostic performance of FL in discrim-
inating IBD from IBS; 2) used endoscopic and histo-
logical methods as the reference standards; 3) presented
sufficient information to calculate the true-positive (TP),
false-positive (FP), true-negative (TN), and false-negative
(FN) rates; and 4) were conducted on human subjects
including pediatric or adult population. Letters, reviews,
conference abstracts, comments and case reports were
excluded because of the limited data presented. When
the same population was reported in two or more publi-
cations, only the most informative or complete study
was included to avoid duplication of information.
Data extraction and quality assessment
The same reviewers (XZ and WX) independently re-
trieved specific data from each full-text article using a
standard data extraction form, which included author,year of publication, nation, patient characteristics, FL
assay, and cutoff value. The published values for TP, FP,
TN, and FN were extracted and used to construct a 2 ×
2 contingency table. Disagreement between the two re-
viewers was resolved by consensus. If consensus among
the two reviewers could not be reached, a third investi-
gator (XT) was referred to for arbitration and consensus.
The methodological quality of the included studies was
evaluated using the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS) list [19], which consists of
14 items scored as “yes”, “no” or “unclear”.
Statistical analysis
Statistical analyses were performed using Meta-Disc
software version 1.4 (for Windows; XI Cochrane Collo-
quium; Barcelona, Spain) and STATA statistical software
version 12.0 (StataCorp; College Station, TX, USA). For
each study, the following indexes of test accuracy were
computed by constructing a 2 × 2 contingency table: sen-
sitivity, specificity, positive likelihood ratio (PLR), nega-
tive likelihood ratio (NLR), and diagnostic odds ratio
(DOR). A random-effects model was used to calculate
the pooled diagnostic indices, with corresponding 95%
confidence intervals (CIs), across studies. A summary re-
ceiver operating characteristic (sROC) curve was plotted
to determine the relationship between sensitivity and
specificity, and the area under the curve (AUC), an ana-
lytical summary of the test performance, was deter-
mined, with the upper and lower limits of the 95% CI of
the AUC calculated as AUC + 1.96 Se and AUC–1.96 Se,
respectively. Heterogeneity was assessed by determining
the Cochran Q-statistic and by the test of inconsistency
(I2) [20], with a P-value < 0.05 or I2 > 50% suggesting
significant heterogeneity [21]. A random effects model,
which considered both within- and between-study varia-
tions [22], was used throughout because of the observa-
tional nature of most studies. In addition, the Spearman’s
rank correlation coefficient was calculated to assess the
threshold effect. Finally publication bias was deter-
mined using Egger precision weighted linear regression
tests [23].
Results
The initial literature search identified a total of 311 re-
ports; of these, 270 were excluded based on their titles
and abstracts (Figure 1). A review of the full text of the
remaining 41 articles led to an additional 34 being ex-
cluded because of failure to meet the inclusion criteria,
duplicate publication or not reporting the data required
to create a contingency table. Finally, seven eligible stud-
ies were included [3,10-15] (Table 1).
The seven eligible studies included a total of 1336 pa-
tients, including 737 with IBD, 381 with IBS, and 218
healthy volunteers, who underwent FL testing. One study
Figure 1 Flowchart of the study selection process.
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and healthy control; that study combined these two groups
for comparisons with patients with IBD [10]. Another
study only reported the TP, FP, TN, and FN rates of FL
assay in distinguishing active IBD from IBS [14]. As our
aim was to observe the diagnostic performance of FL in
differentiating IBD from IBS, our meta-analysis included
1012 patients, 609 with IBD, 381 with IBS and 22 healthy
volunteers. Of the seven included studies, one measured
FL solely in children and young adults [10], three measured
FL in both children and adults [12-14], and the other three
measured FL in adults only [3,11,15]. All seven studiesused a commercially available enzyme-linked immunosorb-
ent assay (IBD-SCAN®, Techlab, Blacksburg, VA, USA) to
measure FL. The methodological quality of the included
studies is presented in Figure 2. Assessment of each risk of
bias item is shown as a percentage across all of the in-
cluded studies (Figure 3).
Figure 4(A) shows the Forest plot for sensitivity and
Figure 4(B) shows the Forest plot for specificity of FL in
discriminating between IBD and IBS. Sensitivities ranged
from 0.69 to 0.86 (pooled sensitivity 0.78; 95% CI: 0.75,
0.82) and specificities from 0.83 to 1.00 (pooled specifi-
city 0.94; 95% CI: 0.91, 0.96). The pooled PLR was 12.31
Table 1 Characteristics of the studies included in the meta-analysis
Study Year Age(mean/
range)
Nation Number of patients FL assay Cut off Test result SEN (95% CI) SPE (95% CI)
IBD UC CD IBS control TP FP FN TN
Walker 2007 13.4/2-21 American 141 62 79 7 22 IBD-SCAN 7.25 ug/ml 118 1 23 28‡ 0.84 (0.77-0.89) 0.97 (0.82-1.00)
Schoepfer 2008 20-79 Switzerland 64 28 36 30 42 IBD-SCAN 7.0 ug/ml 55 1 9 29 0.86 (0.75-0.93) 0.97 (0.83-1.00)
Langhorst 2008 15-70 Germany 85 42 43 54 - IBD-SCAN 7.05 ug/ml 68 1 17 45 0.80 (0.70-0.88) 0.83 (0.71-0.92)
Kane 2003 10-78 American 149 71 78 31 56 IBD-SCAN 4 ug/g 111 0 38 31 0.74 (0.67-0.81) 1.00 (0.89-1.00)
Schroder 2007 20-75 Germany 45 20 25 31 - IBD-SCAN 7.3 ug/g 37 0 8 31 0.82 (0.68-0.92) 1.00 (0.89-1.00)
Sidhu 2010 42/58/56* UK 230 126 104 137 98 IBD-SCAN 7.25 ug/g 70§ 6 32 131 0.69 (0.59-0.77) 0.96 (0.91-0.98)
Otten 2008 52.3/44.5† Netherlands 23 - - 91 - IBD-SCAN 7.25 mg/ml 18 9 5 82 0.78 (0.56-0.93) 0.90 (0.82-0.95)
*Numbers are mean values for IBS, UC and CD respectively. †Numbers are mean values for IBS and IBD respectively.
‡Include 22 healthy volunteers. §Only calculated active IBD.
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0.23 (95% CI: 0.18, 0.29; Figure 4(D)), and the pooled
DOR was 52.65 (95% CI: 25.69, 107.91; Figure 5). The
chi-square values for sensitivity, specificity, PLR, NLR
and DOR were 11.93 (P = 0.063), 18.68 (P = 0.005), 15.01
(P = 0.020), 11.35 (P = 0.078), and 9.49 (P = 0.148), re-
spectively and their I2 values were 49.7%, 67.9%, 60.0%,Figure 2 Methodological quality of each included study. +, Yes; −, No;47.1%, and 36.8%, respectively. Significant heterogeneity
among were observed for specificity and PLR.
The Spearman’s rank correlation coefficient, performed
as a test for threshold effect, was found to be −0.198
(P = 0.670), indicating that no threshold effect could
have caused variations in accuracy estimates among the
individual studies.?, unclear.
Figure 3 Assessment of methodological quality items shown as percentages across all included studies.
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with a standard error (SE) of 0.02. The 95% CI was
0.90–0.98, while the pooled diagnostic accuracy (Q*)
was 0.88 (SE 0.01), demonstrating that FL was highly
able to differentiate between IBD and IBS.
The Egger test showed that the potential publication
bias was significant (P < 0.05). Owing to the limited
number of studies included in our meta-analysis, funnel
plots were not assessed.Figure 4 Forest plots of sensitivity (A), specificity (B), positive likeliho
95% CIs of FL in distinguishing IBD from IBS. The size of the solid circleDiscussion
FL assays may detect mucosal inflammatory activity at a
level insufficient to cause increases in erythrocyte sendi-
mentation rate (ESR) and C-reactive protein (CRP). FL
levels are apparently unaffected by a variety of non-
intestinal conditions that elevate markers of systemic in-
flammation [24]. Lactoferrin is highly stable in feces for
up to 7 days at room temperature [9], enabling patients
to conveniently collect samples at home and transportod ratio (C), and negative likelihood ratio (D) with corresponding
indicates the effect size of each study.
Figure 5 Forest plots of diagnostic odds ratio with corresponding 95% CIs of FL in distinguishing IBD from IBS.
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quantitative FL levels can be easily and reliably mea-
sured by commercially available enzyme-linked immu-
noabsorbent assay kits that have been approved by the
US Food and Drug Administration [5,25]. FL concentra-
tions have been found to correlate well with endoscopic
and histological activity [4,26-29]. Moreover, FL mea-
surements can be used to evaluate responses to anti
TNF-α treatment [30,31] or to predict relapse in IBD pa-
tients [10,32]. Studies have sought to evaluate the accur-
acy of FL in the diagnosis of organic (versus functional)
intestinal diseases, mainly to discriminate IBD from non
inflammatory conditions, especially IBS. Few studies to
date have directly compared the diagnostic performanceFigure 6 Summary ROC curves for FL in discriminating IBD from IBS.
included in the meta-analysis. The regression sROC curves summarize the oof fecal lactoferrin and Cal tests, with some reporting
that both are similar in their ability to detect intestinal
inflammation [11,12,29], while others found that Cal
[3,17] or FL [33] is more accurate diagnostically. LF
seems to be more stable at room temperature and there-
fore may be preferred if long delays are expected before
analysis. Age-related variability seems to be less pro-
nounced with lactoferrin and therefore may be preferable
in pediatric patients [34]. To our knowledge, this study is
the first meta-analysis to assess the diagnostic perform-
ance of FL in differentiating between IBD and IBS.
The present meta-analysis demonstrated that FL level
had a pooled sensitivity of 0.78 and a pooled specificity
of 0.94 in distinguishing IBD (active and inactive) fromThe size of the solid circle represents the sample size of each study
verall diagnostic accuracy
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ing a promising discriminative ability. The DOR, defined
as the ratio of the odds of positive test results between
the diseased and non diseased groups, with higher values
indicating greater accuracy, was 52.65 [35]. Likelihood
ratio is a metric that incorporates both the sensitivity
and specificity, is less affected by prevalence, and is
widely considered more useful in clinical practice [36].
Although there is no absolute threshold, a good diagnos-
tic test may have a PLR >5 and an NLR <0.2 [37]. We
observed a PLR of 12.31, indicating that patients with
IBD had an approximately 12.31-fold higher chance of
testing positive than patients with IBS. We also observed
an NLR of 0.23, indicating that a patient with IBD had a
23% chance of testing negative.
The 1012 patients analyzed in our study included both
children and adults. Although FL has been reported to
vary by age in healthy volunteers [38], the results from the
seven included studies showed no significant difference
between children and adults. These findings suggested
that FL assays could be utilized in a wide spectrum of age
groups. Most of the included studies [3,10-14] contained
patients with IBD of different disease severity, with FL be-
ing a more sensitive assay in patients with active than in-
active IBD. Because the data were insufficient and the
various studies utilized different clinical activity indices,
our analysis failed to stratify patients by disease activity.
Nevertheless, several studies have found that FL levels are
higher in patients with inactive IBD than in patients with
IBS [10,12-14].
Ulcerative colitis (UC) and Crohn’s disease (CD) are two
types of IBD with different inflammatory patterns. UC is
primarily characterized by superficial inflammation of the
colon with neutrophil infiltration, the obligatory involve-
ment of the rectum in some adult patients or the left
colon, together with superficial inflammation, leading to a
short transit time of released FL. In contrast, patients with
CD show small intestinal involvement, with a longer tran-
sit time and/or the accumulation of inflammatory cells in
deeper mucosal layers possibly resulting in FL levels being
higher in CD than in UC [4,39]. In contrast, one study re-
ported higher FL concentrations in CD [13], and another
showed that FL levels tended to be higher in patients with
isolated colonic disease than in patients with involvement
of the ileum alone or the ileocolon [3].Owing to data limi-
tations, we did not perform subgroup analysis based on
disease type and location.
Our study had several limitations. First, all studies in-
cluded in our meta-analysis were from western coun-
tries, which may have biased our findings. Second, our
meta-analysis was based on published studies; the exclu-
sion of unpublished data (grey literature) is generally as-
sociated with an overestimation of the true effect, thus
resulting in a publication bias. Third, the reliability ofthe pooled estimates was dependent on the methodo-
logical quality of the included studies. Although eligible
studies met many of the QUADAS criteria, weaknesses
remained. Fourth, some degree of heterogeneity was in-
troduced by the variability in patient characteristics.
These individuals had different types of IBD, different
disease activity and different sites of inflammation.
Owing to the small number of people included in this
meta-analysis and the lack of available information, we
did not perform subgroup analysis by pretest probability
of CD or UC (based on clinical assessment), or by dis-
ease severity or distribution. Fifth, one study included in
our meta-analysis pooled data from IBS patients and
healthy controls. Since healthy individuals were not rep-
resentative of the study population, it may have gener-
ated some heterogeneity. Sixth, although all included
studies measured FL using the same assay, the thresh-
olds varied, perhaps owing to differences in subject pro-
file or inclusion or exclusion criteria. Therefore, we
could not determine an optimum cutoff value for FL.
Conclusions
This meta-analysis showed that FL appears to have good
diagnostic precision in distinguishing IBD from IBS both
in adults and children. Owing to study limitations, add-
itional high-quality original studies (especially in patients
stratified by disease type, severity and distribution) are
required to confirm the predictive value of FL.
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